Amylin Pharmaceuticals Inc. (AMLN)

[SeriousMoney]

Amylin Pharmaceuticals "outperform," target price raised - update
Tuesday, February 28, 2006 2:29:23 AM ET
Piper Jaffray



NEW YORK, February 28 (newratings.com) - Analysts at Piper Jaffray maintain their "outperform" rating on Amylin Pharmaceuticals (AMLN.NAS). The target price has been raised from $50 to $52.

In a research note published yesterday, the analysts mention that a recent survey on the current prescribers indicates that the adoption of the company’s Byetta drug is expected to increase by 140% over the next one year. The survey reflects that there is a possibility of Amylin Pharmaceuticals posting 4Q06 drug sales ahead of the estimates and the consensus by 25%-30%, the analysts say.

http://www.newratings.com/analyst_news/article_1216114.html